{"entity":{"id":"nct04675294","kind":"trial","name":"Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)","aka":[],"tldr":"A phase 2 trial of Evorpacept, Pembrolizumab in head and neck squamous cell carcinoma, run by ALX Oncology Inc., active and no longer recruiting.","summary":"Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) is a phase 2 interventional study registered as NCT04675294 by ALX Oncology Inc., with 189 participants enrolled, started 2021-04-02 and due to reach its primary completion in 2025-03-03. Interventions recorded: evorpacept, pembrolizumab. Conditions listed: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04675294","url":"https://clinicaltrials.gov/study/NCT04675294"}],"tags":["ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["evorpacept","pembrolizumab"],"companies":["alx-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04675294","phase":"2","setting":"A Phase 2 Study of ALX148 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)","sponsor":"ALX Oncology Inc.","enrolled":189,"outcomes":[]},"route":"/trials/nct04675294/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"evorpacept","kind":"drug","name":"Evorpacept","route":"/drugs/evorpacept/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"alx-oncology","kind":"company","name":"ALX Oncology","route":"/companies/alx-oncology/"}]}}